You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科與視方極聯合發佈單劑量鹽酸氮䓬斯汀滴眼液(順敏®)過敏性結膜炎治療添加新方案
格隆匯 02-25 20:57

廣州,2025年2月25日 – 致力於眼科療法的研發、生產及商業化,以滿足巨大醫療需求缺口的領先眼科製藥企業兆科眼科有限公司(“兆科眼科"; 香港聯交所股份代號:6622)之全資附屬子公司,兆科(廣州)眼科藥物有限公司,與國內眼科醫藥創新型企業浙江視方極醫藥科技有限公司(“視方極"),聯合發佈國內首款單劑量不含抑菌劑的鹽酸氮斯汀滴眼液產品(順敏®),爲過敏性結膜炎患者提供更全面的治療方案選擇。

近年來,中國國內過敏性結膜炎的發病率逐年上升,預計到2030年,全國過敏性結膜炎患者將超過3億人[ 數據來源:弗若斯特沙利文]。鹽酸氮䓬斯汀滴眼液的推出有望爲廣大過敏性結膜炎患者帶來新的希望,3分鐘迅速起效,持續時間長達10小時[ 數據來源:Friedlaender MH, Harris J, LaVallee N, Russell H, Shilstone J. 使用過敏原激發模型評估氮卓斯汀滴眼液 (0.05%) 與安慰劑對過敏性結膜炎患者起效和作用持續時間的評價。眼科學。 2000;107(12):2152-2157.doi:10.1016/s0161-6420(00)00349-3]。0.4毫升單支裝不添加抑菌劑,更適合長期治療的慢性反覆發作患者。該產品的成功上市不僅有助於進一步滿足臨牀用藥需求,也爲過敏性結膜炎患者提供了優質的治療選擇。

此次兆科眼科和視方極的聯手合作是雙方在眼科藥物領域發展的重要里程碑。結合兆科眼科的商業化實力及視方極的產品研發優勢,雙方加強互補合作,共同開闢過敏性結膜炎藥物治療新篇章。隨着兩家公司在眼科藥物領域的持續深耕,中國眼科治療領域可望迎來更多的創新成果,爲患者提供更安全更高效的解決方案。未來,兆科眼科與視方極將繼續攜手前行,共同推動眼科健康事業的發展,爲更多患者帶來希望與光明。

關於浙江視方極醫藥科技有限公司

浙江視方極醫藥科技有限公司作爲國內眼科醫藥領域的新銳力量,自2021年於浙江杭州創立以來,始終堅持以創新驅動發展,構建眼科全產業鏈佈局。 公司重點佈局眼科藥物研發與產業化,產品管線覆蓋近視防控、糖尿病視網膜病變、乾眼、視疲勞、過敏性結膜炎、眼部感染、非感染性眼部炎症、眼科表面麻醉等治療領域,當前有20多款特色仿製藥項目正在推進,其中多款產品有望填補國內臨牀治療空白。憑藉其獨特的差異化產品佈局和持續的技術創新,視方極醫藥正快速成長爲一傢俱備國際競爭力的眼科醫藥創新型企業。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account